IPO 申购指南 国恩科技（2768.HK） 建议申购 2026-1-27 星期二 | 【招股详情】 | | | | --- | --- | --- | | 保荐人 | 招商证券国际 | | | 上市日期 | 年 2026 | 月 日（星期三） 2 4 | | 招股价格 | 34~42 | 港元/股（中间价：38 港元/股） | | 集资额 | 10.577 | 亿港元（扣除包销费及佣金，按中间价计算） | | 每手股数 | 200 股 | | | 入场费 | 8,484.71 | 港元 | | 招股日期 | 2026 年 | 1 月 27 日-2026 年 1 月 30 日 | | 国元证券认购截止日期 | 2026 年 | 1 月 29 日 | | 招股总数 | 3,000 | 万股(可予调整及视乎超额配售权的行使情况而定) | | 国际配售 | 2,700 | 万股(可予调整及视乎超额配售权的行使情况而定)，约占 90% | | 公开发售 | 300 | 万股(可予调整及视乎超额配售权的行使情况而定)，约占 10% | 【申购建议】 公司是一家专注于化工新材料及明胶、胶原蛋白上下游产品的中国供货商。 公 ...

Investment Rating - The report assigns a "Buy" rating for the company, Lepu Biopharma (2157.HK), marking its first coverage [1]. Core Insights - The company is entering a harvest period for new drug approvals, having established a comprehensive pipeline in oncology that includes immunotherapy, ADC (Antibody-Drug Conjugate) targeted therapy, and oncolytic virus drugs. The company has multiple ADC drugs and other therapies in clinical stages, with expectations for new drug approvals in the next 3-5 years [3][10]. - The ADC pipeline is characterized by unique features and competitive advantages in various indications, with MRG003 (EGFR ADC) already approved for NPC (nasopharyngeal carcinoma) in China and showing promising results in other indications [4][30]. - The introduction of oncolytic virus therapy CG0070 has shown potential in the bladder cancer market, with successful regulatory progress in the U.S. and ongoing clinical trials in China [5][30]. - Financially, the company has achieved its first profit and positive operating cash flow in the first half of 2025, with steady revenue growth driven by business development and sales [25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, with a pipeline that includes immunotherapy, ADCs, and oncolytic virus therapies. It has developed a robust ADC technology platform and has multiple products in various stages of clinical development [11][10]. - The pipeline includes 6 ADC drugs and 1 oncolytic virus therapy, with several candidates in pivotal clinical stages, indicating a well-structured development strategy [14][10]. Unique Features of ADCs - MRG003 has been approved for NPC and is in advanced trials for HNSCC (head and neck squamous cell carcinoma) and NSCLC (non-small cell lung cancer), showcasing its broad applicability and competitive edge [30][4]. - Other ADCs in development, such as MRG004A for pancreatic cancer and MRG006A for liver cancer, are also progressing well, with MRG004A entering pivotal trials [30][6]. Financial Performance and Projections - The company reported revenues of 4.66 billion yuan in the first half of 2025, a significant increase from 1.33 billion yuan in the same period of 2024. The net profit for the same period was 290 million yuan, marking a turnaround from a loss of 197 million yuan in the previous year [25][30]. - Revenue projections for 2025, 2026, and 2027 are estimated at 8.8 billion yuan, 10.2 billion yuan, and 14.9 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [30].

Investment Rating - The report assigns a positive investment rating, suggesting active attention to the company due to its operational efficiency and industry improvement [4]. Core Insights - The company is expected to achieve a net profit of approximately 2.65 billion RMB for the fiscal year 2025, representing a significant year-on-year increase of about 57.2% from 1.69 billion RMB in the previous year, exceeding prior expectations [2][3]. - The growth in net profit is attributed to increased operating revenue and improved product profitability, aligning with previous assessments regarding the release of high-value orders and potential for margin expansion [2]. - The company has a robust order backlog, particularly in coal power orders, which are expected to be a core profit contributor in the short to medium term, while long-term growth is anticipated from equipment exports and other energy-related projects [3]. Summary by Sections Financial Performance - The projected net profit for 2025 is 2.65 billion RMB, a 57.2% increase compared to the previous year [2]. - The increase in profitability is driven by revenue growth and enhanced product margins [2]. Order Backlog and Future Growth - The company maintains a strong order backlog, with coal power orders expected to contribute significantly to profits in the near term [3]. - Long-term growth prospects are supported by energy equipment exports and other projects, which are anticipated to gain momentum in the later stages of the current five-year plan [3]. Investment Recommendation - The report recommends active monitoring of the company, highlighting its status as a quality state-owned enterprise with improving operational efficiency and a favorable industry outlook [4].

Investment Rating - The report recommends subscription for the company, Guo'en Technology, with an IPO price range of HKD 34 to HKD 42 per share, suggesting a valuation of approximately 15 times the net profit for 2024 [3]. Core Insights - Guo'en Technology is a Chinese supplier focused on chemical new materials and gelatin, serving both the chemical and health industries. It ranks as the second-largest organic polymer modified materials and composite materials company in China by sales revenue, with a market share of 2.5% [2]. - The global polymer materials market is projected to grow from RMB 29.89 trillion in 2020 to RMB 45.61 trillion by 2024, with a compound annual growth rate (CAGR) of 11.1%. The Chinese polymer materials market is expected to expand from RMB 11.08 trillion in 2020 to RMB 16.28 trillion by 2024, with a CAGR of 10.1% [2]. - The company's revenue for 2022, 2023, and 2024 is forecasted to be RMB 13.41 billion, RMB 17.44 billion, and RMB 19.19 billion, respectively, reflecting a CAGR of 19.6%. Net profits for the same years are projected at RMB 663.11 million, RMB 465.89 million, and RMB 676.38 million [3]. Summary by Relevant Sections IPO Details - The IPO is set to raise HKD 10.577 billion, with a total offering of 30 million shares, of which 27 million shares are allocated for international placement and 3 million shares for public offering [1]. Market Position - Guo'en Technology is the second-largest producer of bone gelatin and the second-largest domestic brand producer of hollow capsules in China, indicating a strong market presence [2]. Financial Performance - The company is currently in a stable growth phase, with a significant safety margin in its valuation based on the IPO pricing compared to its A-share closing price [3].

当前价：76.35 港元 作者 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 2026 年 1 月 27 日 公司研究 大手笔收购 PUMA29%股权，多品牌全球化布局再一里程碑 ——安踏体育（2020.HK）拟收购公告点评 买入（维持） 分析师：孙未未 执业证书编号：S0930517080001 021-52523672 sunww@ebscn.com 分析师：朱洁宇 执业证书编号：S0930523070004 021-52523842 zhujieyu@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 27.97 | | 总市值(亿港元)： | 2135.24 | | 一年最低/最高(港 | 73.55-106.30 | | 元)： | | | 近 3 月换手率： | 32.2% | 股价相对走势 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | -10.2 | -10.8 | -37.1 | | 绝 ...

哈尔滨电气（1133.HK） 2026-01-27 星期二 即时点评 25 年预计录得 26.5 亿元归母净利润，超预期 【事件】 公司于 2026 年 1 月 26 日晚间公告盈利预告，初步评估，预期公司 2025 年度录得归母净利润约 26.5 亿元（上年同期为人民币 16.9 亿元），同比 大幅增长。主要原因为公司 2025 年度营业收入较去年有所增长，产品盈 利能力进一步提高。 【点评观点】 1. 公司 2025 年度净利润同比+57.2%，超预期： 公司预计 2025 年实现归母净利润 26.5 亿元，同比增长约 57.2%，超过我 们预测的 25 亿元的预期。期间净利润大幅增长主要原因包括营业收入增 长、产品盈利能力进一步提高。这与我们此前对公司前期收获的高价值订 单将逐步释放，毛利率仍有上升空间的判断一致；同时由于公司生产规模 扩大，智能化制造能力显著增强，企业的规模效应和运营效率大幅提升。 2. 短中期优质订单继续释放，中长期设备出口等业务提供持续性： 我们认为短中期公司在手订单依旧充沛，我们预期公司煤电订单在"十五 五前期"依旧是利润贡献核心，"十五五中后期"逐步实现平稳，公司抽 蓄和核电订 ...

证券研究报告 | 2026年01月23日 2026年01月24日 2026年01月27日 特步国际（01368.HK） 第四季度主品牌流水持平，索康尼增长超 30% |  | 公司研究·海外公司快评 |  | 纺织服饰·服装家纺 |  投资评级：优于大市（维持） | | --- | --- | --- | --- | --- | | 证券分析师： | 丁诗洁 | 0755-81981391 | dingshijie@guosen.com.cn | 执证编码：S0980520040004 | | 证券分析师： | 刘佳琪 | 010-88005446 | liujiaqi@guosen.com.cn | 执证编码：S0980523070003 | 事项： 公司公告：1 月 23 日，公司发布 2025 年第四季度及全年营运状况，第四季度特步主品牌线上线下全渠道 零售销售流水同比持平，零售折扣7.0-7.5折；索康尼品牌线上线下全渠道零售销售流水同比增长超过30%； 2025 全年，特步主品牌全渠道零售销售流水同比增长低单位数，年末渠道库销比约 4.5 个月；索康尼品牌 线上线下全渠道零售销售流水同比增长超 ...

Investment Rating - The investment rating for the company is "Outperform" (Maintain) [4] Core Views - The company has initiated systematic adjustments in core areas such as products, management, and channels since Q4 2025, alongside a share buyback plan that enhances operational confidence, thereby strengthening the fundamental logic [4] - Due to intensified industry competition, the profit forecasts for 2025-2027 have been revised downwards, with expected net profits of $0.33 million (down $0.05 million), $0.48 million (down $0.07 million), and $0.61 million (down $0.10 million) respectively, representing year-on-year growth of 0.3%, 43.0%, and 27.9% [4] Financial Summary and Valuation Metrics - Revenue projections for 2025-2027 are $186 million, $249 million, and $311 million, with year-on-year growth rates of 17.8%, 34.1%, and 24.6% respectively [9] - The projected P/E ratios for 2025-2027 are 18.7, 13.1, and 10.2 times [9] - The company maintains a gross margin of approximately 32.0% for 2025 and a net margin of 18.0% [9] Market Position and Growth Drivers - The main brand, If Coconut Water, is performing better than the industry and competitors due to its natural quality and first-mover advantage, expected to continue leading the market in 2026 [5] - The secondary brand, Inno Coco, faced sales pressure but has completed major adjustments and expanded partnerships, with new high-value electrolyte beverage products expected to drive growth in 2026 [5] Strategic Partnerships and Expansion - A strategic cooperation agreement was signed with COFCO's subsidiary, which will enhance the company's domestic market strategy by leveraging COFCO's extensive distribution network, facilitating nationwide product coverage [6] - The establishment of the If brand's China headquarters in Shanghai aims to improve local operations and management efficiency, addressing industry challenges such as price disorder and channel management [7]

证券研究报告 | 公司点评 | 服装家纺 跑步心智向上，索康尼如期靓丽 ——特步国际点评报告 投资要点 ❑ 公司发布 2025Q4 运营情况，特步主品牌流水同比持平，零售环境疲软下维持稳 健；索康尼流水同比+30%以上，线下高速增长，电商调整顺利。2025 年全年特 步主品牌流水低单位数增长，索康尼流水同比+30%以上，全年目标顺利达成。 ❑ 主品牌：Q4 流水持平，25 年低单增长，跑步户外增长领跑 特步主品牌 25Q4 流水同比持平，Q4 分月来看,10-11 月流水表现好于 12 月；25 年流水低单位数增长，受跑步品类和电商渠道均双位数增长拉动，整体维持稳健 增长态势，跑步品牌势能持续向上，25 年 11 月上海马拉松赛事中公司旗舰碳板 跑鞋 160X 7.0 PRO 助力运动员丰配友斩获男子组冠军，特步品牌全局选手穿着 率继续稳居第一达到 21.5%。主品牌 25Q4 折扣 70-75 折，同比持平，25 年末库 销比约 4.5 个月，库存状况健康，折扣较为可控。 ❑ 索康尼：店效快速提升，电商调整顺利 索康尼 25Q4 和 25 全年流水均同比增长 30%以上，顺利完成全年目标，Q4 增长 环比加 ...

Investment Rating - The report does not explicitly provide an investment rating for Gushengtang (2273 HK) Core Insights - Gushengtang announced plans to issue US$110 million (approximately HK$857 million) in convertible bonds with a 2% coupon rate and a 5-year maturity, aimed at share repurchases, AI-powered TCM system development, and working capital replenishment [1][5] - The issuance is fully underwritten by funds managed by Boyu Capital, with a controllable equity dilution of 8.91% post-full conversion [1][5] - The expected settlement date for the bond issuance is February 12 [1][5] Summary by Sections Event - Gushengtang plans to issue convertible bonds to raise approximately HK$857 million, with a 2% interest rate and a 5-year term, to support share buybacks, AI system development, and working capital [1][5] Commentary - The low-interest convertible bond issuance is seen as beneficial for stabilizing market expectations, with four key advantages: 1. Strategic endorsement from Boyu Capital, which may accelerate business expansion and diversify customer acquisition channels [2][7] 2. Low-cost financing minimizes interest burden while keeping dilution impact manageable [2][7] 3. Enhanced cash reserves provide greater flexibility for future repurchases or expansion initiatives [2][7] 4. Allocation of funds towards TCM AI system development addresses the industry challenge of a shortage of renowned traditional Chinese medicine practitioners [2][7]